Emerging Weight Loss Stocks Gain Too (OREX, ARNA, MNKD)

Posted in pre-market 
September 9th, 2009

Two VIVUS (VVUS) competitors are running despite the notion that the great study results may actually increase the competitive threat against them.  It seems the thought is that this will make them hurry with more data now… This is running over into other diabetes and obesity emerging stocks as well.
Orexigen Therapeutics Inc. (NASDAQ: OREX) is up almost 4% at $8.50 on over 107,000 shares pre-market.  Arena Pharmaceuticals Inc. (NASDAQ: ARNA) is up over 6% at $4.90 on 215,000 shares pre-market.  Data 9:03 AM EST.

The second line of companies includes MannKind Corp. (NASDAQ: MNKD) up 3% at $9.00 on about 10,000 shares.


Comments are closed